For investors, biotech enthusiasts, and healthcare innovators — this New To The Street interview features Cuong Do, President & CEO of BioVie (NASDAQ: BIVI), and Frank Aquila, Senior M&A Partner at Sullivan & Cromwell, for a dual deep dive into biotech breakthroughs and global dealmaking trends.
Cuong Do shares major progress on BioVie’s Parkinson’s disease clinical trial, accelerated with support from the Michael J. Fox Foundation, as well as its expanding Long COVID program at top U.S. institutions including Mayo Clinic, Yale, and UCSF. He explains how the company’s drug candidate targets TNF-alpha inflammation, offering potential for the first new Parkinson’s therapy in 50 years and a breakthrough for Long COVID brain fog and fatigue.
Then, Frank Aquila discusses the evolving M&A landscape, from AI-driven due diligence to a surge in mega-deals ($5B+), and why North America’s tech and financial sectors are leading global consolidation. He also forecasts a strong 2026 outlook for strategic transactions amid cautious optimism on regulation and inflation.
Watch this NewsOut special for insights bridging biotech innovation and corporate dealmaking in the AI era.